Latest News about FDA
Recent news which mentions FDA
Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges
December 19, 2024
From Benzinga
What's Going On With Tonix Pharmaceuticals Stock Today?
December 17, 2024
From Benzinga
FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer
December 17, 2024
From Benzinga
From Benzinga
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
December 16, 2024
From Benzinga
America's $300 Billion Moonshot: The Medicare Guide Program
December 12, 2024
From Benzinga
DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids
December 12, 2024
From Benzinga
Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?
December 10, 2024
From Benzinga
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?
December 10, 2024
From Benzinga
Financial Crime Weekly: CEO Sentenced To 51 Months In Prison, Kiromic BioPharma Charged With Failure To Disclose Material Information
December 07, 2024
From Benzinga
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
December 06, 2024
From Benzinga
Merus Scores Its First FDA Approval For Lung Cancer Drug
December 05, 2024
From Benzinga
FDA Approves AstraZeneca's Blockbuster Cancer Drug Imfinzi For Aggressive Form Of Lung Cancer
December 05, 2024
From Benzinga
Supreme Court Hears Case Against FDA Ban On Flavored Vapes: Here Are The Stocks To Watch
December 02, 2024
From Benzinga
FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy
November 29, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.